Medivir Posts Q1 Revenue Growth and Shrinking EBITDA Loss Amid Progress in Clinical Trials

Medivir (ST:MVIR) revealed a modest boost in first-quarter revenue, reaching SEK 1 million, while its EBITDA loss showed noticeable improvement, narrowing to SEK 8.8 million. These figures suggest the company is gaining some footing as it advances through demanding clinical development stages.

The Nordic drug developer recently wrapped up a directed share issue totalling SEK 45 million, reinforcing its cash position. CEO Jens Lindberg highlighted that this capital injection bolsters Medivir's capacity to push forward with the clinical program for MIV-711, their osteoarthritis drug candidate.

By the quarter's end, Medivir's cash and cash equivalents had climbed to SEK 149.1 million, providing a wider financial runway for ongoing and upcoming trials. Despite the increased liquidity, the adjusted free cash flow registered a negative SEK 13 million, reflecting ongoing investment in research and development.

Strategically, the company is gearing up to launch a phase 2 proof-of-concept study for MIV-711 targeting Osteogenesis Imperfecta, a brittle bone disease. Additionally, plans are set to initiate a randomized trial with fostrox as a second-line treatment option in liver cancer, signaling expansion in Medivir's oncological pursuits.

Operational progress is steady, as Lindberg mentioned that starting and preparing these clinical trials have helped advance the company's drug development pipeline, with an eye on refining product candidates that could potentially reshape treatment options in their focus areas.

On the veterinary front, Medivir is anticipating data from an ongoing MIV-701 study, with results expected by the fourth quarter of 2026. This parallel research stream showcases the company's diverse approach to drug development across human and animal health.

The company's Q1 activity reflects cautious optimism, balancing clinical ambition with fiscal discipline. While revenues remain modest, the narrowing EBITDA loss and improved cash reserves suggest a firm focused on moving its pipeline forward.

Medivir's next big milestone will likely be the outcome of the phase 2 study for MIV-711, which could redefine its position in both clinical development and investor interest.